Premium
Trends in the incidence of use of noninsulin glucose‐lowering drugs between 2006 and 2013 in France
Author(s) -
Arnaud Mickael,
Bezin Julien,
Bégaud Bernard,
Pariente Antoine,
Salvo Francesco
Publication year - 2017
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/fcp.12298
Subject(s) - incidence (geometry) , medicine , confidence interval , population , metformin , demography , endocrinology , diabetes mellitus , environmental health , mathematics , geometry , sociology
This study aimed at describing trends in the incidence of use of noninsulin glucose‐lowering drugs ( NIGLD s) between 2006 and 2013 in France. Repeated cross‐sectional studies on NIGLD new users were performed annually from 2006 to 2013 within the Echantillon Généraliste des Bénéficiaires ( EGB ) database, a 1/97th representative sample of the population covered by the French healthcare insurance system. NIGLD included metformin, sulfonylureas, α‐glucosidase inhibitors, thiazolidinediones, dipeptidylpeptidase‐4 ( DPP ‐4) inhibitors, glinides and glucagon‐like peptide‐1 analogues. New users were defined as patients with no delivery of any NIGLD (first‐line new users) or no delivery of a NIGLD of the same class (add‐on/switch new users) in the preceding year. Incidence rates of use and corresponding 95% confidence intervals (95% CI ) were estimated per 1000 persons. Among the 507 043 persons included in the EGB in 2006, 2036 were identified as NIGLD first‐line new users and 2192 as add‐on/switch new users, which corresponded to an incidence of use of 4.0‰ (95% CI 3.8–4.2) and 4.3‰ (4.1–4.5), respectively. First‐line incidence increased to 5.3‰ (5.1–5.5) in 2010 and then decreased to 4.2‰ (4.0–4.4) in 2013; add‐on/switch incidence increased to 8.0‰ (7.8–8.2) in 2010 and then decreased to 5.3‰ (5.1–5.5) in 2013. This reduction was mainly related to DPP ‐4 inhibitors, whose use as add‐on/switch NIGLD s was roughly halved between 2010 and 2013. Concomitantly, the use of sulfonylureas and glinides increased. In conclusion, after reaching a peak in 2010, the incidence of use of NIGLD s has markedly decreased in France. Since then, prescribers seem to have reverted to older and well‐known therapies.